{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:29:49Z","timestamp":1783618189771,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40263-023-01048-x","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T20:03:01Z","timestamp":1700164981000},"page":"941-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"37","author":[{"given":"Laila","family":"Aboulatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abou-Setta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Askin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheda","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekhya","family":"Lavu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Peymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zarychanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Eltonsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"ML Lonneke","year":"2006","unstructured":"Lonneke ML, de Lau MMB. The epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5:525\u201335.","journal-title":"Lancet Neurol"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00023210-200923080-00007","volume":"23","author":"R Yan","year":"2009","unstructured":"Yan R, Cai H, Cui Y, et al. Zonisamide: in Parkinson\u2019s disease. CNS Drugs. 2009;23:703\u201311.","journal-title":"CNS Drugs"},{"key":"1048_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/CSHPERSPECT.A033118","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A033118.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583\u201390.","journal-title":"Mov Disord"},{"key":"1048_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2019.00372","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang Y, Zhu K, Chi S, Wang C, Xie A. Emerging role of sirtuin 2 in Parkinson\u2019s Disease. Front Aging Neurosci. 2019. https:\/\/doi.org\/10.3389\/FNAGI.2019.00372.","journal-title":"Front Aging Neurosci."},{"key":"1048_CR6","doi-asserted-by":"crossref","unstructured":"Greenamyre JT, Hastings TG. Biomedicine. Parkinson\u2019s: divergent causes, convergent mechanisms. Science. 2004;304:1120\u20132.","DOI":"10.1126\/science.1098966"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S1353-8020(09)70770-9","volume":"15","author":"EC Wolters","year":"2009","unstructured":"Wolters EC. Non-motor extranigral signs and symptoms in Parkinson\u2019s disease. Park Relat Disord. 2009;15:S6-12.","journal-title":"Park Relat Disord."},{"key":"1048_CR8","first-page":"168","volume":"18","author":"DF Boland","year":"2012","unstructured":"Boland DF, Stacy M. The economic and quality of life burden associated with Parkinson\u2019s disease: a focus on symptoms. Am J Manag Care. 2012;18:168\u201375.","journal-title":"Am J Manag Care"},{"key":"1048_CR9","first-page":"229","volume":"5","author":"W Poewe","year":"2010","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229\u201338.","journal-title":"Clin Interv Aging"},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog Neurobiol. 2015;132:96\u2013168.","journal-title":"Prog Neurobiol"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33:1248\u201366.","journal-title":"Mov Disord"},{"key":"1048_CR12","unstructured":"NICE. Overview: Parkinson\u2019s disease in adults: guidance. https:\/\/www.nice.org.uk\/guidance\/NG71. Accessed 27 Mar 2022."},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"4817488","DOI":"10.1155\/2022\/4817488","volume":"2022","author":"L Kong","year":"2022","unstructured":"Kong L, Xi J, Jiang Z, Yu X, Liu H, Wang Z. Zonisamide\u2019s efficacy and safety on Parkinson\u2019s Disease and dementia with lewy bodies: a meta-analysis and systematic review. Biomed Res Int. 2022;2022:4817488.","journal-title":"Biomed Res Int"},{"key":"1048_CR14","first-page":"e29118","volume":"14","author":"J Sharaf","year":"2022","unstructured":"Sharaf J, Williams K-AD, Tariq M, et al. The efficacy of safinamide in the management of Parkinson\u2019s Disease: a systematic review. Cureus. 2022;14:e29118.","journal-title":"Cureus."},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/JAD-161068","volume":"56","author":"S Matsunaga","year":"2017","unstructured":"Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for Parkinson\u2019s disease: a meta-analysis. J Alzheimer\u2019s Dis. 2017;56:1229\u201339.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"1048_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV, editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). 2022. www.training.cochrane.org\/handbook. Accessed 27 Mar 2023."},{"key":"1048_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/BMJ.N71.","journal-title":"BMJ"},{"key":"1048_CR18","unstructured":"Higgins JPT, Savovi J, Page MJ, Elbers RG, SterneJAC. Chapter 8: Assessing risk of bias in a randomized trial. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-08. Accessed 27 Mar 2022."},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1503\/cmaj.060410","volume":"176","author":"JPA Ioannidis","year":"2007","unstructured":"Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176:1091\u20136.","journal-title":"CMAJ"},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","volume":"76","author":"M Murata","year":"2020","unstructured":"Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a phase 3 randomized clinical trial. Park Relat Disord. 2020;76:91\u20137.","journal-title":"Park Relat Disord."},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","volume":"68","author":"M Murata","year":"2007","unstructured":"Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68:45\u201350.","journal-title":"Neurology"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord. 2015;30:1343\u201350.","journal-title":"Mov Disord"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ncn3.12026","volume":"4","author":"M Murata","year":"2016","unstructured":"Murata M, Hasegawa K, Kanazawa I, et al. Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease. Neurol Clin Neurosci. 2016;4:10\u20135.","journal-title":"Neurol Clin Neurosci"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology. 2018;90:e664\u201372.","journal-title":"Neurology"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2022.10.017","volume":"105","author":"K Pillai","year":"2022","unstructured":"Pillai K, Bhat P, Kumar A, Rajan R, Bhushan M, Vishnu, et al. Zonisamide add-on in tremor-dominant Parkinson\u2019 s disease: a randomized controlled clinical trial. Park Relat Disord. 2022;105:1\u20136.","journal-title":"Park Relat Disord."},{"key":"1048_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mds.23954","volume":"27","author":"F Stocchi","year":"2012","unstructured":"Stocchi F, Borgohain R, Onofrj M, Schapira AHV, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson\u2019s disease patients. Mov Disord. 2012;27:106\u201312.","journal-title":"Mov Disord"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1212\/01.WNL.0000134672.44217.F7","volume":"63","author":"F Stocchi","year":"2004","unstructured":"Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746\u20138.","journal-title":"Neurology"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 2017;74:216\u201324.","journal-title":"JAMA Neurol"},{"key":"1048_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study. Park Relat Disord. 2020;75:17\u201323.","journal-title":"Park Relat Disord."},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29:1273\u201380.","journal-title":"Mov Disord"},{"key":"1048_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1468-1331.2012.03840.x","volume":"20","author":"AHV Schapira","year":"2013","unstructured":"Schapira AHV, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson\u2019s disease. Eur J Neurol. 2013;20:271\u201380.","journal-title":"Eur J Neurol"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"Q Wei","year":"2022","unstructured":"Wei Q, Tan Y, Xu P, et al. The XINDI Study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson\u2019s disease with motor fluctuations. CNS Drugs. 2022;36:1217\u201327.","journal-title":"CNS Drugs"},{"key":"1048_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.866502","volume":"13","author":"J Kulisevsky","year":"2022","unstructured":"Kulisevsky J, Martinez-Horta S, Campolongo A, Pascual-Sedano B, Marin-Lahoz J, Bejr-kasem H, et al. A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with Parkinson\u2019s Disease. Front Neurol. 2022;13: 866502.","journal-title":"Front Neurol"},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29:229\u201337.","journal-title":"Mov Disord"},{"key":"1048_CR36","unstructured":"ClinicalTrials.gov. Xadago report (2013): safinamide in early IPD , as add-on to dopamine agonist (MOTION). NCT00605683. Committee for Medicinal Products for Human Use (CHMP): p. 1\u20139"},{"key":"1048_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56:251\u201361.","journal-title":"Clin Pharmacokinet"},{"key":"1048_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","volume":"35","author":"C Cattaneo","year":"2018","unstructured":"Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson\u2019s Disease chronic pain. Adv Ther. 2018;35:515\u201322.","journal-title":"Adv Ther"},{"key":"1048_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JPD-191765","volume":"10","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Jost WH, Bonizzoni E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s disease patients. J Parkinsons Dis. 2020;10:89\u201397.","journal-title":"J Parkinsons Dis"},{"key":"1048_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, M\u00fcller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C. Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s Disease. J Parkinsons Dis. 2017;7:629\u201334.","journal-title":"J Parkinsons Dis"},{"key":"1048_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jagp.2021.07.002","volume":"30","author":"T Odawara","year":"2022","unstructured":"Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, Kosaka K, et al. Long-term efficacy and safety of zonisamide for treatment of parkinsonism in patients with dementia with lewy bodies: an open-label extension of a phase three randomized controlled trial. Am J Geriatr Psychiatry. 2022;30:314\u201328.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1048_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40263-015-0247-x","volume":"29","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Kurtis MM. Impact of pharmacotherapy on quality of life in patients with Parkinson\u2019s disease. CNS Drugs. 2015;29:397\u2013413.","journal-title":"CNS Drugs"},{"key":"1048_CR43","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol. 2015;22:1184\u201391.","journal-title":"Eur J Neurol"},{"key":"1048_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2020.574652","volume":"14","author":"C Li","year":"2020","unstructured":"Li C, Xue L, Liu Y, Yang Z, Chi S, Xie A. Zonisamide for the treatment of Parkinson disease: a current update. Front Neurosci. 2020;14:1\u201312.","journal-title":"Front Neurosci"},{"key":"1048_CR45","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1007\/s10072-021-05550-2","volume":"42","author":"A Goel","year":"2021","unstructured":"Goel A, Sugumaran R, Narayan SK. Zonisamide in Parkinson\u2019s disease: a current update. Neurol Sci. 2021;42:4123\u20139.","journal-title":"Neurol Sci"},{"key":"1048_CR46","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1586\/14737175.7.9.1077","volume":"7","author":"H Miwa","year":"2007","unstructured":"Miwa H. Zonisamide for the treatment of Parkinson\u2019s disease. Expert Rev Neurother. 2007;7:1077\u201383.","journal-title":"Expert Rev Neurother"},{"key":"1048_CR47","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","volume":"17","author":"M Onofrj","year":"2008","unstructured":"Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson\u2019s disease. Expert Opin Investig Drugs. 2008;17:1115\u201325.","journal-title":"Expert Opin Investig Drugs"},{"key":"1048_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","volume":"31","author":"HA Blair","year":"2017","unstructured":"Blair HA, Dhillon S. Safinamide: a review in Parkinson\u2019s disease. CNS Drugs. 2017;31:169\u201376.","journal-title":"CNS Drugs"},{"key":"1048_CR49","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/ene.15651","volume":"30","author":"R Yan","year":"2023","unstructured":"Yan R, Cai H, Cui Y. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson\u2019s disease: a network meta-analysis of randomized controlled. Eur J Neurol. 2023;30:1118\u201334.","journal-title":"Eur J Neurol"},{"key":"1048_CR50","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40261-021-01011-y","volume":"41","author":"R Giossi","year":"2021","unstructured":"Giossi R, Carrara F, Mazzari M, et al. Overall efficacy and safety of safinamide in Parkinson\u2019s disease: a systematic review and a meta-analysis. Clin Drug Investig. 2021;41:321\u201339.","journal-title":"Clin Drug Investig"},{"key":"1048_CR51","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S0028-3932(01)00055-0","volume":"39","author":"R Blesa","year":"2001","unstructured":"Blesa R, Pujol M, Aguilar M, et al. Clinical validity of the \u201cmini-mental state\u201d for Spanish speaking communities. Neuropsychologia. 2001;39:1150\u20137.","journal-title":"Neuropsychologia"},{"key":"1048_CR52","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.apnu.2016.01.015","volume":"30","author":"JC Tsai","year":"2016","unstructured":"Tsai JC, Chen CW, Chu H, Yang HL, Chung MH, Liao YM, et al. Comparing the sensitivity, specificity, and predictive values of the Montreal Cognitive Assessment and Mini-Mental State Examination when screening people for mild cognitive impairment and dementia in Chinese population. Arch Psychiatr Nurs. 2016;30:486\u201391.","journal-title":"Arch Psychiatr Nurs"},{"key":"1048_CR53","unstructured":"Fiorenzato E, Zurlo L, Cianci C, Garon M, Gandolfi T, Pistonesi F, et al. MoCA and MMSE subitems\u2019 sensitivity across the PD-cognitive spectrum [abstract]. Mov Disord. 2023;37 (suppl 2)."},{"key":"1048_CR54","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/jnnp.2006.111161","volume":"78","author":"P Hagell","year":"2007","unstructured":"Hagell P, Nygren C. The 39 item Parkinson\u2019s disease questionnaire (PDQ-39) revisited: Implications for evidence based medicine. J Neurol Neurosurg Psychiatry. 2007;78:1191\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1048_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00427-0","author":"P Stathis","year":"2022","unstructured":"Stathis P, Papadopoulos G. Evaluation and validation of a patient-reported quality-of-life questionnaire for Parkinson\u2019s disease. J Patient-Reported Outcomes. 2022. https:\/\/doi.org\/10.1186\/s41687-022-00427-0.","journal-title":"J Patient-Reported Outcomes."},{"key":"1048_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/PL00007730","volume":"245 Suppl.","author":"V Peto","year":"1998","unstructured":"Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson\u2019s Disease quality of life questionnaire and its associated measures. J Neurol. 1998;245 Suppl.:10\u20134.","journal-title":"J Neurol"},{"key":"1048_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson\u2019s disease questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing. 1997;26:353\u20137.","journal-title":"Age Ageing"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01048-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T13:17:57Z","timestamp":1700745477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01048-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01048-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"23 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laila Aboulatta, Lara Haidar, Ahmed Abou-Setta, Nicole Askin, Rasheda Rabbani, Alekhya Lavu, Payam Peymani, Ryan Zarychanski, and Sherif Eltonsy have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LA, AA, RR, RZ, NA, and SE contributed to the conception and design of the study. LA and NA performed the literature search. LA, LH, AL, and PP conducted the screening and data extraction. LA conducted the data analysis. LA, AA, RR, and SE contributed to the data interpretation. LA drafted the manuscript. AA, RR, RZ, NA, PP, AL, LH, and SE critically revised the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}